Accenture vs Roche: Founders, CEOs and History
Accenture was founded in 1989 by Arthur Andersen Consulting Partners, George Shaheen and is led by Julie Sweet. Roche was founded in 1896 by Fritz Hoffmann-La Roche and is led by Thomas Schinecker.
Company facts
Founders
Accenture
Arthur Andersen Consulting Partners
Accenture has no single founder. It began in the early 1950s as the business and technology consulting practice of Arthur Andersen, the accounting firm founded in 1913.
George Shaheen
George Shaheen led Andersen Consulting from 1989 until September 1999. By the time he left, the consulting unit had about 65,000 staff. In 1997 it began the ICC arbitration to separate from Arthur Andersen.
Roche
Fritz Hoffmann-La Roche
Fritz Hoffmann-La Roche (1868-1920) founded F. Hoffmann-La Roche & Co. in Basel on 1 October 1896, at age 28.
CEOs and their tenures
Accenture
- George Shaheen1989–1999
Managing Partner and CEO, Andersen Consulting
Led Andersen Consulting from its 1989 formation as a separate unit of Andersen Worldwide until September 1999, a period in which the consulting unit grew to about 65,000 employees and began the 1997 ICC arbitration to leave Arthur Andersen.
Source - Joe Forehand1999–2004
CEO
Succeeded Shaheen in November 1999 as global managing partner and CEO. Led the firm through the August 2000 arbitration ruling, the January 1, 2001 rename to Accenture and the July 19, 2001 NYSE IPO at $14.50 per share.
Source - William D. Green2004–2011
CEO
CEO from Sept 1, 2004 to January 2011, after serving as chief operating officer for client services. Revenue was $23.09B in FY2010, his last full fiscal year as CEO.
Source - Pierre Nanterme2011–2019
CEO
CEO from January 2011 and also chairman from February 2013. Revenue grew from $27.35B in FY2011 to $41.60B in FY2018 as originally reported.
Source - David Rowland2019–2019
Interim CEO
Chief financial officer who served as interim CEO from Jan 10, 2019 after Nanterme stepped down, until Julie Sweet took over on Sept 1, 2019.
Source - Julie Sweet2019–present
Chair and CEO
CEO since Sept 1, 2019 and chair since Sept 1, 2021; previously CEO of Accenture North America and, before that, general counsel. Revenue rose from $44.33B in FY2020 to $69.67B in FY2025, and headcount reached about 799,000 by May 31, 2026.
Source
Roche
- Severin Schwan2008–2023
Chief Executive Officer
Serving as CEO from 2008 to 2023, he cemented Roche's absolute dominance in global oncology and highly advanced diagnostics before moving to Chairman of the Board.
Source - Thomas Schinecker2023–present
Chief Executive Officer
Under Schinecker, Roche returned to growth after the COVID testing decline: 2025 sales rose 7% at constant rates to ~$73.8 billion (CHF 61.5 billion) and 12 late-stage studies read out positively that year.
Source
Timeline: Accenture and Roche side by side
1896Roche
F. Hoffmann-La Roche Founded in Basel
Fritz Hoffmann-La Roche founds the enterprise in Basel, Switzerland, pioneering mass-manufactured, chemically standardized prescription pharmaceuticals.
1898Roche
Commercial Breakthrough with Sirolin
Roche launches non-prescription cough syrup Sirolin, achieving widespread international distribution and financing early clinical laboratories.
1934Roche
First Industrial Synthesis of Vitamin C
Roche becomes the first company to mass-produce synthetic Vitamin C (Redoxon) at industrial scale, anchoring decades of high-margin global cash flow.
1953Accenture
Arthur Andersen GE feasibility study
Arthur Andersen's administrative services group, led by Joseph Glickauf, carries out a study for General Electric on computerizing payroll at Appliance Park in Louisville, Kentucky.
1963Roche
Launch of Valium (Diazepam)
Roche introduces Valium, which becomes the world's most widely prescribed psychotropic medication and establishes global pharmaceutical leadership.
1968Roche
Establishment of Roche Diagnostics
Roche launches its dedicated diagnostic division, laying the foundation to become the world's preeminent in-vitro diagnostics (IVD) provider.
1989Accenture
Andersen Consulting formed
Arthur Andersen and Andersen Consulting become separate units of Andersen Worldwide Societe Cooperative, with George Shaheen as managing partner and CEO of the consulting unit. The more profitable unit pays the other up to 15% of profits.
1997Accenture
Arbitration with Arthur Andersen begins
Andersen Consulting files an arbitration claim with the International Chamber of Commerce, arguing that Arthur Andersen broke their agreement by building its own competing consulting practice.
2000Accenture
Arbitration ruling and Avanade
In April 2000 Andersen Consulting and Microsoft form Avanade, a joint venture now majority owned by Accenture.
2001Accenture
Rename to Accenture and NYSE IPO
Andersen Consulting becomes Accenture on Jan 1, 2001, a name based on "Accent on the future" suggested by an employee in Oslo. The Bermuda-incorporated company prices its IPO at $14.50 per share and starts trading on the NYSE on July 19, 2001.
2004Accenture
William D. Green becomes CEO
William D. Green succeeds Joe Forehand as CEO on Sept 1, 2004; Forehand remains chairman.
2008Roche
Severin Schwan becomes CEO
Severin Schwan became CEO of F. Hoffmann-La Roche in 2008. Led Roche for 14 years; handed over to Thomas Schinecker in March 2023 and became chairman.
2009Accenture
Reincorporation in Ireland
On May 26, 2009 the board approves moving the company's place of incorporation from Bermuda to Ireland, which remains its legal domicile.
2009Roche
Full Acquisition of Genentech for $46.8 Billion
Roche completes its historic $46.8 billion buyout of American biotechnology pioneer Genentech, securing market leadership in oncology biologics.
2011Accenture
Pierre Nanterme becomes CEO
Pierre Nanterme becomes CEO in January 2011. The same year Accenture completes its purchase of insurance software company Duck Creek Technologies.
2013Accenture
Fjord acquisition
Accenture agrees in May 2013 to acquire Fjord, a service design consultancy, adding design capacity to Accenture Interactive.
2016Accenture
Duck Creek stake sold to Apax
Funds advised by Apax Partners buy a 60% stake in Duck Creek Technologies from Accenture, which keeps 40%.
2018Roche
Foundation Medicine & Flatiron Health Acquisitions
Roche acquires Foundation Medicine and Flatiron Health, integrating real-world oncology data analytics and genomic profiling into personalized healthcare.
2019Accenture
CEO transition and Droga5
Nanterme steps down for health reasons on Jan 11, 2019 and CFO David Rowland becomes interim CEO. Accenture Interactive completes the purchase of creative agency Droga5, and Julie Sweet becomes CEO on Sept 1, 2019.
2022Accenture
Accenture Song
On April 26, 2022 Accenture Interactive begins going to market as Accenture Song. FY2022 revenue rises 22% to $61.59B.
2023Accenture
$3B Data & AI investment
In June 2023 Accenture announces a $3B investment over three years in its Data & AI practice and a plan to double AI talent to 80,000 people.
2023Roche
Acquired Telavant
F. Hoffmann-La Roche acquired Telavant for $7.1 billion. Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.
2024Accenture
Udacity acquisition
Accenture completes its purchase of online education company Udacity on May 20, 2024 to support its Accenture LearnVantage training business.
2025Accenture
FY2025 results and restructuring
FY2025 revenue reaches $69.67B with $80.62B in new bookings. In September 2025 Accenture outlines a six-month, $865M business optimization program, mainly severance, and moves to a single Reinvention Services unit.
2025Roche
Group Sales Reach CHF 61.5 Billion
Under CEO Thomas Schinecker, Roche delivers group sales of ~$73.8 billion (CHF 61.5 billion), driven by ~$57.2B (CHF 47.7B) in Pharmaceuticals and ~$16.6B (CHF 13.8B) in Diagnostics.
2026Accenture
Faculty and Ookla deals
Accenture completes the acquisition of UK AI company Faculty on March 16, 2026 and agrees in March 2026 to buy Ziff Davis's connectivity division (Ookla, Speedtest, Downdetector) for $1.2B in cash. Q3 FY2026 revenue is $18.72B.
Acquisitions
Accenture
- Faculty2026Undisclosed
- Ookla (Ziff Davis Connectivity division)2026$1.2B
- Udacity2024Undisclosed
- umlaut2021Undisclosed
- Droga52019Undisclosed
- Fjord2013Undisclosed
Roche
- PathAI2026$1.1B
- 89bio2025$3.5B
- Telavant2023$7.1B
- Carmot Therapeutics2023$2.7B
- Foundation Medicine2018$2.4B
- ForSight VISION42017Undisclosed
Questions about Accenture vs Roche
Who is the CEO of Accenture PLC and F. Hoffmann-La Roche AG?
Accenture PLC is led by Julie Sweet and F. Hoffmann-La Roche AG is led by Thomas Schinecker. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Accenture PLC founded vs F. Hoffmann-La Roche AG?
F. Hoffmann-La Roche AG was founded in 1896 — 93 years before Accenture PLC, which was founded in 1989. F. Hoffmann-La Roche AG's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Accenture PLC.
How many employees does Accenture PLC have compared to F. Hoffmann-La Roche AG?
Accenture PLC employs approximately 799,000 people, while F. Hoffmann-La Roche AG employs approximately 112,774. Accenture PLC has the larger workforce at 799,000 employees, compared to F. Hoffmann-La Roche AG's 112,774. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Accenture PLC and F. Hoffmann-La Roche AG headquartered?
Accenture PLC is headquartered in Ireland and F. Hoffmann-La Roche AG is headquartered in Switzerland. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Accenture PLC and F. Hoffmann-La Roche AG?
Accenture PLC was founded by Arthur Andersen Consulting Partners, George Shaheen. F. Hoffmann-La Roche AG was founded by Fritz Hoffmann-La Roche.
Which company has a longer operating history — Accenture PLC or F. Hoffmann-La Roche AG?
F. Hoffmann-La Roche AG has been operating for approximately 130 years, making it the more established of the two companies. Accenture PLC has been in operation for around 37 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Accenture vs Roche overview